Superpharm’s diazepam tablets
Executive Summary
Superpharm contends in July 23 letter to FDA that proposed withdrawal of its three diazepam ANDAs "should be rescinded" in light of a new in vivo bioavailability study and in vitro dissolution and stability data that demonstrate bioequivalency of its diazepam to Roche's Valium. The submission was filed to support Superpharm's request for a hearing.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.